Celladon (NASDAQ:CLDN) prices its public offering of 4M shares of common stock at $9.50 per share generating gross proceeds of ~$38M. Underwriters over-allotment is 600K shares. Closing date is August 18, 2014.
Net proceeds will fund R&D activities pertaining to its lead product candidate Mydicar, the development of commercial manufacturing capabilities, working capital and general corporate purposes.
CLDN closed yesterday at $9.65.